1. The Chemokine CCL3 Regulates Myeloid Differentiation and Hematopoietic Stem Cell Numbers
- Author
-
Alexandra N Goodman, Daniel K. Byun, Mary A. Georger, Rhonda J. Staversky, Michael W. Becker, Laura M. Calvi, Benjamin J. Frisch, and Brandon J. Zaffuto
- Subjects
0301 basic medicine ,Myeloid ,Cellular differentiation ,lcsh:Medicine ,Cell Count ,Biology ,Article ,03 medical and health sciences ,Mice ,immune system diseases ,hemic and lymphatic diseases ,parasitic diseases ,medicine ,Animals ,Myeloid Cells ,Progenitor cell ,lcsh:Science ,Chemokine CCL3 ,Mice, Knockout ,Multidisciplinary ,lcsh:R ,Hematopoietic stem cell ,hemic and immune systems ,Cell Differentiation ,respiratory system ,medicine.disease ,Hematopoietic Stem Cells ,3. Good health ,Haematopoiesis ,Leukemia ,030104 developmental biology ,medicine.anatomical_structure ,Cancer research ,lcsh:Q ,Bone marrow ,Chronic myelogenous leukemia - Abstract
The chemokine CCL3 is frequently overexpressed in malignancies and overexpression leads to microenvironmental dysfunction. In murine models of chronic myelogenous leukemia (CML), CCL3 is critical for the maintenance of a leukemia stem cell population, and leukemia progression. With CCL3 implicated as a potentially viable therapeutic target, it is important to carefully characterize its role in normal hematopoietic homeostasis. CCL3−/− mice were used to evaluate the role of CCL3 in regulating hematopoietic stem and progenitor cell (HSPC) populations. CCL3−/− mice had loss of mature myeloid populations, while myeloid progenitors and HSPCs were increased, and microenvironmental populations were unchanged. These data show that CCL3 promotes myeloid lineage differentiation and the size of the HSPC pool independent of the supportive bone marrow microenvironment. Our results demonstrate a previously unrecognized role of CCL3 in the maintenance of homeostatic hematopoiesis that should be evaluated when targeting CCL3 signaling for the treatment of hematologic malignancy.
- Published
- 2018